Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs

CCI-779 is an ester of the immunosuppressive agent sirolimus (rapamycin) that causes cell-cycle arrest at G1 via inhibition of key signaling pathways resulting in inhibition of RNA translation. Antitumor activity has been demonstrated using cell lines and animal models of malignant glioma. Patients...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Investigational new drugs 2004-11, Vol.22 (4), p.427-435
Hauptverfasser:	Chang, Susan M, Kuhn, John, Wen, Patrick, Greenberg, Harry, Schiff, David, Conrad, Charles, Fink, Karen, Robins, H Ian, Cloughesy, Timothy, De Angelis, Lisa, Razier, Jeffrey, Hess, Kenneth, Dancey, Janet, Prados, Michael D
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Anticonvulsants - administration & dosage Anticonvulsants - pharmacokinetics Anticonvulsants - toxicity Antineoplastic Agents - administration & dosage Antineoplastic Agents - pharmacokinetics Antineoplastic Agents - toxicity Brain cancer Brain Neoplasms - drug therapy Cancer therapies Chemotherapy Cohort Studies Cytochrome Cytochrome P-450 Enzyme System - biosynthesis Dose-Response Relationship, Drug Drug Administration Schedule Drug dosages Drug Interactions Enzyme Induction Enzymes Epilepsy Female Glioma Glioma - drug therapy Humans Immunosuppressive agents Infusions, Intravenous Kinases Male Maximum Tolerated Dose Medical prognosis Metabolism Middle Aged Neoplasm Recurrence, Local Patients Pharmacokinetics Proteins Radiation Sirolimus - administration & dosage Sirolimus - analogs & derivatives Sirolimus - pharmacokinetics Sirolimus - toxicity Toxicity Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!